Practical Considerations to Implement the Shorter Regimen to MDR-TB Patients in China.
Q. Liu,F. Sun,Y. Li,J. Bao,Y. Zhang,W. Zhang
DOI: https://doi.org/10.1016/j.cmi.2018.04.026
IF: 13.31
2018-01-01
Clinical Microbiology and Infection
Abstract:For the past 5 years, tuberculosis (TB) has been one of the top 10 causes of death worldwide from a single infectious agent, ranking above HIV/AIDS [[1]World Health Organization Global tuberculosis report.2017http://www.who.int/tb/publications/global_report/en/Date accessed: January 24, 2018Google Scholar]. Management and eradication of this disease is being hindered by the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). Globally, in 2016, there were estimated 10.4 million cases of TB and 490 000 cases of MDR-TB [[1]World Health Organization Global tuberculosis report.2017http://www.who.int/tb/publications/global_report/en/Date accessed: January 24, 2018Google Scholar]. China accounts for around 8.6% (0.895/10.4 million) of the global TB burden, ranking third in the top three countries (India, Indonesia, China) with the highest number of TB cases, and ranking first with the largest number of MDR/rifampin-resistant (RR)-TB cases. In 2016, the treatment success rate for MDR-TB using the 18-24-month conventional World Health Organization (WHO) regimen was estimated to be about 54% worldwide and 41% for China, which remains unacceptably low [[1]World Health Organization Global tuberculosis report.2017http://www.who.int/tb/publications/global_report/en/Date accessed: January 24, 2018Google Scholar]. In May 2016, the WHO conditionally recommended a standardized, shorter regimen for MDR-pulmonary TB (PTB). The regimen includes kanamycin (an injectable agent), moxifloxacin (MFX), prothionamide (PTO), clofazimine (CFZ), isoniazid (INH), pyrazinamide (PZA), and ethambutol (EMB), given together in an initial phase of 4 months (with the possibility to extend to 6 months if patients remain sputum smear-positive at the end of month 4), followed by 5 months of treatment with four of the drugs (MFX, CFZ, PZA, and EMB). The recommendation was based on successful experiences in Bangladesh and several African countries. By 2016, 35 countries, mostly in Africa and Asia, had introduced this shorter regimen for treatment of MDR-TB/RR-TB, with high treatment success rates (87–90%) [[1]World Health Organization Global tuberculosis report.2017http://www.who.int/tb/publications/global_report/en/Date accessed: January 24, 2018Google Scholar]. This regimen appears to be an improvement on the traditional 18-24-month one, with attractive characteristics including shorter treatment duration, considerably lower cost, improved outcomes, and better patient adherence. Yet, it has not been used among Chinese patients. The regimen has strict eligibility criteria, with confirmed resistance (except INH resistance) or suspected ineffectiveness to a drug in this regimen being one of the exclusion criteria. It should be used only for ‘simple MDR-TB patients’ who have neither been previously treated with second-line anti-TB drugs, nor are resistant to fluoroquinolones (FQs) or injectable second-line drugs. Hence, doubts have been raised as to the widespread applicability of this regimen. Publications from Europe have reported eligibility proportions ranging from 6.2% to 14% [2Balabanova Y. Fiebig L. Ignatyeva O. Riekstina V. Danilovits M. Jaama K. et al.Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule?.Thorax. 2017; 72: 850-852Crossref PubMed Scopus (25) Google Scholar, 3Lange C. Duarte R. Frechet-Jachym M. Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe.Am J Respir Crit Care Med. 2016; 194: 1029-1031Crossref PubMed Scopus (58) Google Scholar, 4Van der Werf M.J. Hollo V. Kodmon C. Dara M. Catchpole M. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.Eur Respir J. 2017; 49: 1601992Crossref PubMed Scopus (26) Google Scholar, 5Sotgiu G. Tiberi S. D’Ambrosio L. Centis R. Alffenaar J.W. Caminero J.A. et al.Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis.Eur Respir J. 2016; 48: 1503-1507Crossref PubMed Scopus (59) Google Scholar]. Studies from North America and South-Asia have estimated eligibility proportions around 25–30% [6Chee C.B.E. KhinMar K.W. Sng L.H. Jureen R. Cutter J. Lee V.J.M. et al.The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?.Eur Respir J. 2017; 50: 1700753Crossref PubMed Scopus (15) Google Scholar, 7Barry P.M. Lowenthal P. True L. Henry L. Schack G. Wendorf K. et al.Benefit of the shorter multidrug-resistant tuberculosis treatment regimen in California and modified eligibility criteria.Am J Respir Crit Care Med. 2017; 196: 1488-1489Crossref PubMed Scopus (6) Google Scholar], and data from Brazil and Pakistan have shown more optimistic eligibility proportions of 50% or higher [8Dalcolmo M. Gayoso R. Sotgiu G. Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.Eur Respir J. 2017; 49: 1602309Crossref PubMed Scopus (27) Google Scholar, 9Javaid A. Ahmad N. Khan A.H. Shaheen Z. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.Eur Respir J. 2017; 49: 1601967Crossref PubMed Scopus (29) Google Scholar]. As for China, one of the countries with highest estimated numbers of MDR-TB patients, the shorter regimen has not been applied and the eligibility for this regimen has not been reported. According to studies from different regions in China, high rates of resistance to at least one second-line drug (SLDs) among MDR-TB patients were reported from 31.4% to 54.4% [10Chen Y. Yuan Z. Shen X. Wu J. Wu Z. Xu B. Resistance to second-line antituberculosis drugs and delay in drug susceptibility testing among multidrug-resistant tuberculosis patients in Shanghai.Biomed Res Int. 2016; 2016: 2628913PubMed Google Scholar, 11Zhao Y.L. Xu S. Wang L. Chin D.P. Wang S. Jiang G. et al.National survey of drug-resistant tuberculosis in China.N Engl J Med. 2012; 366: 2161-2170Crossref PubMed Scopus (512) Google Scholar]. Furthermore, data from a series of surveys conducted in some provinces in China have revealed that the proportion of MDR-TB with PZA resistance has reached about 50% [12Pang Y. Zhang Z. Wang Y. Wang S. Song Y. Zhao B. et al.Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000 to 2010.Antimicrob Agents Chemother. 2017; 61 (e02170–16)Crossref Scopus (19) Google Scholar, 13Xia Q. Zhao L.L. Li F. Fan Y.M. Chen Y.Y. Wu B.B. et al.Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China.Antimicrob Agents Chemother. 2015; 59: 1690-1695Crossref PubMed Scopus (53) Google Scholar]. For MFX, which plays an important role in the shorter regimen, the prevalence of isolates resistant to MFX in China was increased significantly from 10.7% in 2000 to 42.3% in 2010 [[12]Pang Y. Zhang Z. Wang Y. Wang S. Song Y. Zhao B. et al.Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000 to 2010.Antimicrob Agents Chemother. 2017; 61 (e02170–16)Crossref Scopus (19) Google Scholar]. This relatively high prevalence of MFX resistance could be explained by the fact that FQs have been widely used in treatment of undiagnosed community-acquired respiratory infections for more than two decades in China, as well as having widespread use in animal and food industries [[12]Pang Y. Zhang Z. Wang Y. Wang S. Song Y. Zhao B. et al.Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000 to 2010.Antimicrob Agents Chemother. 2017; 61 (e02170–16)Crossref Scopus (19) Google Scholar]. In addition, the current PZA drug susceptibility test (DST) using the BD MGIT 960 system can be unreliable because of false resistance problems. As a result, not all labs perform PZA DST. Also, there are no reliable methods available to test for susceptibility to CFZ or to PTO. Apparently, there is a huge gap between the need for comprehensive molecular and phenotypic DST results for applying the shorter regimen and the limited resources in clinical practice in China. In addition, 56.3% of MDR-TB patients have been previously treated with first-line anti-TB drugs [[11]Zhao Y.L. Xu S. Wang L. Chin D.P. Wang S. Jiang G. et al.National survey of drug-resistant tuberculosis in China.N Engl J Med. 2012; 366: 2161-2170Crossref PubMed Scopus (512) Google Scholar], which indicates that many patients have been exposed to PZA and EMB and are likely to develop resistance to these two drugs and may not qualify for the shorter regimen. To some extent, the ambiguity of the inclusion and exclusion criteria of the WHO-recommended shorter regimen makes it poorly applicable in high-burden MDR-TB countries with low prevalence of ‘simple MDR-TB’, such as China. The regimen also advocates high-dose INH, which is effective against isolates with low-level INH resistance caused by mutations in the inhA promoter region [[14]Dominguez J. Boettger E.C. Cirillo D. Cobelens F. Eisenach K.D. Gagneux S. et al.Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement.Int J Tuberc Lung Dis. 2016; 20: 24-42Crossref PubMed Scopus (104) Google Scholar]. However, there are no favourable data on the benefit of high-dose INH for isolates with high-level INH resistance caused by mutations in KatG at position 315. Among 128 INH-resistant strains from six provincial TB hospitals in China, the most frequent mutations are KatG315 (70.3%), which is much higher than inhA promoter mutations (8.6%) [[15]Zhao L.L. Chen Y. Liu H.C. Xia Q. Wu X.C. Sun Q. et al.Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from China.Antimicrob Agents Chemother. 2014; 58: 1997-2005Crossref PubMed Scopus (31) Google Scholar]. This suggests that only a small proportion of MDR-TB patients would benefit from high-dose INH therapy as part of the shorter regimen in China. Additionally, CFZ, the drug used in both intensive and continuous phases of the shorter regimen, can cause skin pigmentation. This adverse effect may be a serious concern in many cultures, especially among young Asian women, which may lead to poor adherence. Furthermore, the availability and cost of CFZ would also hinder the immediate adoption of the shorter regimen. As discussed above, the application of the WHO-recommended shorter regimen in China has some challenges to overcome. There is no doubt the shorter regimen has great value for suitable MDR-TB patients, but the question is, how to select the suitable patients in a setting where the patient population can only be identified by appropriate DST. It is important that national TB programmes expand their capacity for broader DSTs for SLDs to enable clinicians to select suitable patients for the WHO-recommended shorter regimen at an earlier stage. Moreover, for Chinese patients, an individualized treatment approach will be proposed based on the reality of the national conditions, the burden of the drug resistance, the affordability of drugs, and the capacity of rapid detection of drug-resistant TB in China. The Chinese government and researchers have invested a great deal of capital and efforts in the control of MDR-TB. According to the preliminary results of an ongoing registered trial (NCT02120638) conducted in China, based on the molecular DST results of PZA, a 12-month regimen is expected to achieve higher treatment success rates among Chinese MDR-TB populations without PZA resistance associated pncA/rpsA mutations. In the future, we believe that with implementation of precision individualized treatment based on rapid molecular DST for SLDs, available, affordable, and effective shorter regimens suitable for Chinese MDR-TB patients will emerge to more effectively control MDR-TB. To summarize, in our opinion, the WHO-recommended shorter regimen would only be beneficial to a small fraction of Chinese MDR-TB patients in a setting with a high proportion of previously treated MDR-TB [[11]Zhao Y.L. Xu S. Wang L. Chin D.P. Wang S. Jiang G. et al.National survey of drug-resistant tuberculosis in China.N Engl J Med. 2012; 366: 2161-2170Crossref PubMed Scopus (512) Google Scholar]. Although the WHO-recommended shorter regimen has advantages of patient adherence, drug safety, and tolerability profile, the efficacy of the shorter regimen still needs to be confirmed by conducting more clinical trials among different regions and populations with variable drug-resistant TB burden. In addition to using the recommended programmatic treatment in appropriate populations, an individualized regimen based on the resistance profile of the bacteria and patients' drug tolerance should be the aim in high-quality treatment for MDR-TB. This work was supported in part by the Key Technologies Research and Development Program for Infectious Diseases of China [2018ZX10722301-003]. All authors report no conflicts of interest relevant to this article.